Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers

Practice changing standardization of lower extremity lymphedema quantitative measurements with integrated patient reported outcomes will likely refine and redefine the optimal risk-reduction strategies to diminish the devastating limb-related dysfunction and morbidity associated with treatment of gynecologic cancers. The National Cancer Institute (NCI), Division of Cancer Prevention brought together a diverse group of cancer treatment, therapy and patient reported outcomes experts to discuss the current state-of-the-science in lymphedema evaluation with the potential goal of incorporating new strategies for optimal evaluation of lymphedema in future developing gynecologic clinical trials. Published by Elsevier Inc.

Automated summary

By practicing changing the standardization of quantitative measurements of lower extremity lymphedema with integrated patient reported outcomes, optimal risk-reduction strategies to diminish limb-related dysfunction and morbidity associated with treatment of gynecologic cancers are likely to be refined and redefined. A diverse group of experts in cancer treatment, therapy, and patient reported outcomes gathered by the National Cancer Institute discussed the current state-of-the-science in lymphedema evaluation, aiming to incorporate new strategies for optimal evaluation of lymphedema in future gynecologic clinical trials.